Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study.

ABSTRACT:

Background

Acute rejection, which includes antibody-mediated rejection and acute cellular rejection, is a risk factor for lung allograft loss. Lung transplant patients often undergo surveillance transbronchial biopsies to detect and treat acute rejection before irreversible chronic rejection develops. Limitations of this approach include its invasiveness and high interobserver variability. We tested the performance of percent donor-derived cell-free DNA (%ddcfDNA), a non-invasive blood test, to detect acute rejection.

Methods

This multicenter cohort study monitored 148 lung transplant subjects over a median of 19.6 months. We collected serial plasma samples contemporaneously with TBBx to measure %ddcfDNA. Clinical data was collected to adjudicate for acute rejection. The pri

SUBMITTER: Jang MK 

PROVIDER: S-EPMC8319066 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature